NeoGenomics, Inc. reported $766M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $766M (to Q2 2026). Net income: −$52M, trailing twelve months to Q2 2026. Free cash flow: −$7.4M, trailing twelve months to Q2 2026. Operating margin: −9.0%, trailing twelve months to Q2 2026.

NEONeoGenomics, Inc.

Healthcare

$16.35+92% 1Y

$16.35

$7.1952 weeks$19.90

NEO as reported

NeoGenomics, Inc. reported $766M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed.

$766M

Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before

Net income: −$52M
Net income · −50% year on year · trailing twelve months to Q2 2026
Free cash flow: −$7.4M
Free cash flow · −62% year on year · trailing twelve months to Q2 2026
Operating margin: −9.0%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NEO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$766M	+11%	Q2 2026
Net income	−$52M	−50%	Q2 2026
EPS	−$0.39	−52%	Q2 2026
Gross margin	44%	n/a	Q2 2026
Operating margin	−9.0%	n/a	Q2 2026
Net margin	−6.9%	n/a	Q2 2026
ROE	−11%	n/a	Q2 2026
ROA	−6.9%	n/a	Q2 2026
ROIC	−4.6%	n/a	Q4 2021 · 18 quarters behind
Free cash flow	−$7.4M	−62%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.